It is well established that coronary artery disease (CAD) is associated with inflammatory processes and coenzyme Q10 may hold a promising role in reducing this inflammation by way of different mechanisms. A group of Taiwanese researchers from Chung Shan Medical University and the Intensive Care Unit of Taichung Veterans General found in a recent study that the nutrient successfully lowered levels of the inflammatory marker IL-6 (interleukin-6) in patients who were given a daily dose of 150 mg coenzyme Q10 for 12 weeks.
The study was conducted on 40 patients with coronary artery disease who were randomly assigned to three groups: a placebo group, a 60 mg/day coenzyme Q10 group, or a 150 mg/day coenzyme Q10 group. All groups followed the prescribed intervention for 12 weeks. Levels of inflammatory markers, including IL-6, C-reactive Protein, and homocysteine, plus superoxide dismutase (an endogenous antioxidant enzyme) were measured before and after.
Subjects in the 150 mg coenzyme Q10 group had significantly lower levels of IL-6 and malondialdehyde (a marker of lipid peroxidation). At the same time, subjects in both Q10 groups had increased superoxide dismutase activity, which is a sign of improved antioxidant protection.
On behalf of these findings, the researchers conclude that coenzyme Q10 taken at a dosage of 150 mg/day appears to decrease the inflammatory marker IL-6 in patients with coronary artery disease.
Source: Nutrition. 2012 Feb 16.